Davita Dialysis At Deborah is a medicare approved dialysis facility center in Browns Mills, New Jersey and it has 15 dialysis stations. It is located in Burlington county at 107 Trenton Road, Browns Mills, NJ, 08015. You can reach out to the office of Davita Dialysis At Deborah at (609) 893-3950. This dialysis clinic is managed and/or owned by Davita. Davita Dialysis At Deborah has the following ownership type - Profit. It was first certified by medicare in April, 2015. The medicare id for this facility is 312648 and it accepts patients under medicare ESRD program.
| Name | Davita Dialysis At Deborah |
|---|---|
| Location | 107 Trenton Road, Browns Mills, New Jersey |
| No. of Dialysis Stations | 15 |
| Medicare ID | 312648 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 107 Trenton Road, Browns Mills, New Jersey, 08015 | |
| (609) 893-3950 | |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
| NPI Number | 1841618907 |
| Organization Name | Dialysis At Deborah |
| Doing Business As | Magoffin Dialysis Llc |
| Address | 107 Trenton Rd Browns Mills, New Jersey, 08015 |
| Phone Number | (615) 320-4414 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 30 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 10 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 54 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 452 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
| Adult patients getting regular peritoneal dialysis at the center | 5 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 32 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita Dialysis At Deborah with elevated calcium levels.
| Patients with hypercalcemia | 58 |
| Hypercalcemia patient months | 487 |
| Patients with Serumphosphor | 59 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 57 |
| Patient months included in arterial venous fistula and catheter summaries | 378 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 56 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 49 |
| Hospitalization Rate in facility | 195.3 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 339.9 |
| Hospitalization Rate: Lower Confidence Limit | 116.6 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita Dialysis At Deborah were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 37.2 |
| Readmission Rate: Lower Confidence Limit | 14.5 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita Dialysis At Deborah get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| SIR: Upper Confidence Limit | .95 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita Dialysis At Deborah's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 41 |
| Transfusion Rate in facility | 34.4 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 111.7 |
| Transfusion Rate: Lower Confidence Limit | 12.2 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita Dialysis At Deborah lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 102 |
| Mortality Rate in facility | 18.9 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 33.9 |
| Mortality Rate: Lower Confidence Limit | 9.4 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago
Davita Dialysis At Deborah Location: 107 Trenton Road, Browns Mills, New Jersey, 08015 Phone: (609) 893-3950 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.
Mayo Clinic has announced the first U.S. stem cell clinical trial for pediatric congenital heart disease. The trial aims to determine how stem cells from autologous umbilical cord blood can help children with hypoplastic left heart syndrome, a rare defect in which the left side of the heart is critically underdeveloped.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
› Verified 6 days ago